SAN DIEGO, March 15, 2011 /PRNewswire/ — iTherX, a
pharmaceutical company dedicated to discovering and developing a
new class of therapies for hepatitis C, today announced that Stefan
Zeuzem, M.D., has joined the company as Chair of the Scientific and
Clinical Advisory Board. Dr. Zeuzem will lead a respected
group of hepatitis thought leaders in contributing their expertise
to the clinical development of iTherX’s lead compound, ITX-5061, a
first-in-class hepatitis C entry inhibitor.
“Stefan Zeuzem brings more than 20 years of international
clinical and research leadership in hepatitis viruses, as well as
liver disease and transplantation to our team. iTherX is fortunate
to have Dr. Zeuzem’s invaluable guidance and perspective as we
advance our lead compound ITX-5061, a hepatitis C viral entry
inhibitor, through clinical development,” said Flossie Wong-Staal,
Ph.D., Chief Scientific Officer of iTherX. “We have
established a truly dynamic and experienced scientific and clinical
advisory board to bring forward this novel class of compounds.
Along with our advisors, we believe ITX-5061 has the promise
of preventing the entry of the hepatitis C virus into cells while
complementing existing antiviral treatment.”
Dr. Zeuzem currently serves as Chief of the Department of
Medicine and Professor of Medicine at the Johann Wolfgang Goethe
University Hospital in Frankfurt, Germany. His clinical areas of
expertise include gastroenterology, hepatology, liver
transplantation, endoscopy, gastrointestinal oncology, and
endocrinology. Dr. Zeuzem’s current research interests include
cellular physiology, molecular biology of hepatitis viruses, viral
kinetics, the role of hepatitis viruses in hepatocarcinogenesis,
and the stratification and optimization of antiviral treatment.
After receiving his medical training from the J.W. Goethe
University Medical School, the University Of Cambridge School Of
Clinical Medicine (United Kingdom), and the Univ
‘/>”/>
